AorticLab’s Post

FLOWer EPD: Championing Safety with Minimal Thrombogenicity in TAVI Procedures   In the intricate world of TAVI, effectively managing thrombogenicity is crucial. FLOWer EPD stands out for its exceptionally low propensity to cause blood clots, ensuring patient safety and procedure success. Let's explore the features that make FLOWer a leader in thrombogenic safety:   🔬 Proven in Studies: Our in vitro studies have thoroughly examined FLOWer's thrombogenicity. The results are clear and reassuring: during procedures, FLOWer exhibited no thrombotic complications, highlighting its safe design and reliable performance.   🌊 Preserving Blood Flow: The design of FLOWer is not just about blocking debris; it's also about maintaining healthy blood flow. The mesh of the device is engineered to allow blood to pass through seamlessly, reducing the risk of clot formation.   💉 Simplified Anticoagulation Protocol: With FLOWer, there's no need for device-specific adjustments to the Activated Clotting Time (ACT). Regular ACT monitoring, as is standard for TAVI procedures, is all that's required. This simplification not only makes the process more straightforward but also aligns with standard procedural protocols.   FLOWer's minimal thrombogenicity is a testament to our commitment to patient safety and procedural excellence. With FLOWer, clinicians can focus on the procedure, reassured by the device's inherent safety features.   Discover the difference with FLOWer – where advanced technology meets patient-first safety.   #TAVI #Cardiology #FLOWerEPD #PatientSafety #AorticStenosis

The first in-human procedures in Abbott’s Volt CE Mark Study using our new Volt™ Pulsed Field Ablation (PFA) System are now complete – marking a significant leap forward in the way physicians will treat and manage atrial fibrillation and other arrhythmias. AFib treatment is still accompanied by recurrent hospital visits, invasive procedures, technical challenges, and complications. As the number of patients continues to grow, so does the need for groundbreaking technological innovation. Unlike any other PFA technology, Abbott’s Volt PFA System extends the PFA promise of safety and speed to better lesion quality and enhanced system ease of use. By combining Volt’s unique balloon-in-basket design with the industry-leading tracking technology of Abbott’s EnSite X EP System, physicians will be equipped to treat patients in accordance with their individual workflow preferences allowing un-compromised safety, efficacy, and speed. #AbbottProud to share the news: https://lnkd.in/gdbahzRk #PulsedFieldAblation #Ablation #AtrialFibrillation #ClinicalTrials #Arrhythmia 

OCT–guided #PCI in high-risk patients results in larger minimum stent area than angiography guidance, but provides no apparent clinical benefit to target-vessel failure at 2 years, according to new data from the ILUMIEN IV trial. #ESCCongress 📑 Read more on #CRTonline. https://ow.ly/4b3p50PEMKK

Truveta Data was recently cited in a REAL-PE study, presented at #TCT2023, demonstrating that the EKOS endovascular system had lower rates of adverse events compared to another leading treatment for patients treated for pulmonary embolism. "According to Boston Scientific, the analysis is the largest comparative study to use near real-time health system-based electronic health record (EHR) data to understand clinical practices and outcomes related to PE." Read more from Cardiovascular News: https://tr.vet/46TYLc7 #PulmonaryEmbolism #PE #PETreatmeants #EKOS #EHRData #HealthTech #MedTech #HealthData #HealthInnovation #MedicalDevice #MedicalTechnology #MedicalData #ClinicalCare

Truveta Data was recently cited in a REAL-PE study, presented at #TCT2023, demonstrating that the EKOS endovascular system had lower rates of adverse events compared to another leading treatment for patients treated for pulmonary embolism. "According to Boston Scientific, the analysis is the largest comparative study to use near real-time health system-based electronic health record (EHR) data to understand clinical practices and outcomes related to PE." Read more from Cardiovascular News: https://tr.vet/46TYLc7 #PulmonaryEmbolism #PE #PETreatmeants #EKOS #EHRData #HealthTech #MedTech #HealthData #HealthInnovation #MedicalDevice #MedicalTechnology #MedicalData #ClinicalCare

More great news coming from FastWave Medical! FastWave Medical has today announced successful 30-day results from the first-in-human study of its innovative system. The study aimed to assess the safety and feasibility of the IVL system in patients with peripheral arterial disease (PAD) affecting the superficial femoral and popliteal arteries with moderate to severe calcium. Key Highlights: ✅ 100% procedural success and 0% peri-procedural adverse events ⬇️ 5.9% mean residual diameter stenosis post-therapy 👏 At 30 days, 0% major adverse events, 100% patency, and 0% revascularization 📈 Patients recoded improved walking distance, speed, stair-climbing ability, and ankle-brachial index #IVL #intravascular #MedTech #medicaldevices